Search results for " preclinical"

showing 10 items of 159 documents

COX-1/COX-2 inhibitors based on the methanone moiety

2002

This paper focuses on the synthesis and the in vitro testing of dual COX-1/COX-2 inhibitors. Starting from structures of non-steroidal anti-inflammatory drugs (NSAIDs) the diaryl methanone element was chosen as a lead. Modifications were carried out on this scaffold to obtain potent inhibitors of the COX enzymes. The N-(2-aroylphenyl)sulphonamides and -amides were studied in detail, and to consolidate the data evaluated the corresponding 3- and 4-regioisomers were also investigated. The potency and the enzyme selectivity were varied by structural modifications of the lead.

Blood PlateletsStereochemistrymedicine.drug_classDrug Evaluation PreclinicalCarboxamideIsozymeChemical synthesisStructure-Activity RelationshipOxazinesDrug DiscoverymedicineAnimalsPotencyMoietyCyclooxygenase InhibitorsPharmacologychemistry.chemical_classificationCyclooxygenase 2 InhibitorsMolecular StructurebiologyChemistryAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral MedicineIn vitroIsoenzymesEnzymeCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorCyclooxygenase 1biology.proteinEuropean Journal of Medicinal Chemistry
researchProduct

In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detect…

2001

Objective and Design: The aim of this study was to develop a new, whole-cell test system which is easy to handle and requires a standard equipment for the parallel screening of COX-1 and COX-2 inhibitors.¶Materials: Bovine aortic endothelial cells (BAECs).¶Treatment and methods: Unstimulated bovine aortic coronary endothelial cells (BAECs) were used as a source of COX-1 and BAECs pretreated with ASA (100 μM) and activated with phorbol myristate acetate (PMA) were used as a source of COX-2. The time- and concentration-dependent induction of COX-2 expression in the BAECs was evaluated by a kinetic profile (HPLC analysis) and detected by Western-Blot analysis using polyclonal antibodies agains…

Blotting WesternImmunologyDrug Evaluation PreclinicalAorta ThoracicIn Vitro TechniquesHigh-performance liquid chromatographyLipoxygenaseDiclofenacmedicineAnimalsCyclooxygenase InhibitorsLipoxygenase InhibitorsIC50Chromatography High Pressure LiquidPharmacologyCyclooxygenase 2 InhibitorsbiologyChemistryMolecular biologyIsoenzymesKineticsMeloxicamBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesPolyclonal antibodiesCyclooxygenase 1biology.proteinTetradecanoylphorbol AcetateAceclofenacCattleSpectrophotometry UltravioletEndothelium VascularCyclooxygenasemedicine.drugInflammation Research
researchProduct

A Neuroprotective Function for the Hematopoietic Protein Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

2007

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic cytokine responsible for the proliferation, differentiation, and maturation of cells of the myeloid lineage, which was cloned more than 20 years ago. Here we uncovered a novel function of GM-CSF in the central nervous system (CNS). We identified the GM-CSF α-receptor as an upregulated gene in a screen for ischemia-induced genes in the cortex. This receptor is broadly expressed on neurons throughout the brain together with its ligand and induced by ischemic insults. In primary cortical neurons and human neuroblastoma cells, GM-CSF counteracts programmed cell death and induces BCL-2 and BCL-Xl expression in a dose- a…

Brain InfarctionMaleProgrammed cell deathTime FactorsMyeloidmedicine.medical_treatmentDrug Evaluation Preclinicalbcl-X ProteinApoptosisBiologyNeuroprotectionBrain IschemiaPhosphatidylinositol 3-KinasesmedicineAnimalsHumansMyeloid CellsRats Long-EvansRats WistarProtein kinase BCell ProliferationCerebral CortexNeuronsDose-Response Relationship DrugGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationNeurodegenerative DiseasesRatsUp-RegulationCell biologyDisease Models AnimalHaematopoiesisNeuroprotective Agentsmedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorNeurologyBlood-Brain BarrierReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologyNeurology (clinical)Signal transductionCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-aktSignal Transductionmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Drug Screening Boosted by Hyperpolarized Long-Lived States in NMR

2014

International audience; : Transverse and longitudinal relaxation times (T1ρ and T1 ) have been widely exploited in NMR to probe the binding of ligands and putative drugs to target proteins. We have shown recently that long-lived states (LLS) can be more sensitive to ligand binding. LLS can be excited if the ligand comprises at least two coupled spins. Herein we broaden the scope of ligand screening by LLS to arbitrary ligands by covalent attachment of a functional group, which comprises a pair of coupled protons that are isolated from neighboring magnetic nuclei. The resulting functionalized ligands have longitudinal relaxation times T1 ((1) H) that are sufficiently long to allow the powerf…

BromidesMagnetic Resonance SpectroscopyStereochemistryDrug Evaluation PreclinicalThiophenesLigands010402 general chemistry01 natural sciencesBiochemistrydynamic nuclear polarizationchemistry.chemical_compoundNMR spectroscopyCatalytic DomainDrug DiscoveryGeneral Pharmacology Toxicology and PharmaceuticsPharmacologySpins[CHIM.ORGA]Chemical Sciences/Organic chemistry010405 organic chemistryDrug discoveryOrganic ChemistryRelaxation (NMR)ProteinsNuclear magnetic resonance spectroscopyFull PapersLigand (biochemistry)0104 chemical sciencesCrystallographychemistryCovalent bondlong-lived statesExcited stateFunctional groupMolecular MedicineChemMedChem
researchProduct

Topical treatment with a two-component gel releasing nitric oxide cures C57BL/6 mice from cutaneous leishmaniasis caused by Leishmania major.

2016

C57BL/6medicine.medical_specialty030231 tropical medicineDrug Evaluation PreclinicalLeishmaniasis CutaneousTopical treatmentDermatologyPharmacologyAdministration CutaneousBiochemistryNitric oxide030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCutaneous leishmaniasismedicineAnimalsLeishmania majorNitric Oxide DonorsMolecular BiologyLeishmania majorbiologybusiness.industryLeishmaniasisbiology.organism_classificationmedicine.diseaseDermatologyMice Inbred C57BLchemistrybusinessGelsExperimental dermatology
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

2014

Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the mutations in a tumour are unique to that single patient and only a small number of mutations are shared between patients, the addressed medical need is modest. A rapidly determined patient-specific tumour mutation pattern combined with a flexible mutation-targeting drug platform could generate a mutation-targeting individualised therapy, which would benefit each single patient. Next-generation sequencing enables the rapid identification of somatic mutations in individual tumours (the mutanome). Immunoinformatics enables predictions of mutat…

Cancer ResearchMutationbusiness.industryGenetic enhancementDrug Evaluation PreclinicalCancerGenomicsmedicine.diseasePrecision medicinemedicine.disease_causeBioinformaticsCancer VaccinesTranslational Research BiomedicalBreast cancerOncologyImmunologyMutationMedicineHumansPersonalized medicineCancer vaccineMinireviewRNA NeoplasmPrecision MedicinebusinessBritish Journal of Cancer
researchProduct

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice

2003

Abstract Purpose The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied. Methods and materials Anemia was induced by total body irradiation ([TBI], 2 × 4 Gy) of mice before tumor implantation into the subcutis of the hind leg. The development of anemia was prevented by rhEPO (750 U/kg s.c.) given 3 times weekly starting 2 weeks before TBI. Fourteen days after fractionated TBI (tumor volume of approx. 40 mm 3 ), single-dose irradiation of the tumor with varying doses was performed so that in full dose–response relationship for the probability of tumor cure was obtained. Results Radiation-i…

Cancer ResearchPathologymedicine.medical_specialtyAnemiamedicine.medical_treatmentTransplantation HeterologousDrug Evaluation PreclinicalUrologyMice NudeHindlimbRadiation ToleranceHemoglobinsMicemedicineAnimalsHumansRadiology Nuclear Medicine and imagingRadiosensitivityddc:610ErythropoietinRadiationbusiness.industryAnemiaSarcomaHypoxia (medical)Total body irradiationmedicine.diseaseCell HypoxiaRecombinant ProteinsRadiation therapyRadiation Injuries ExperimentalOncologyErythropoietinDose Fractionation RadiationHemoglobinmedicine.symptombusinessNeoplasm TransplantationWhole-Body Irradiationmedicine.drug
researchProduct

Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells.

2011

Abstract Artesunate, the active agent from Artemisia annua L. used in the traditional Chinese medicine, is being applied as a first-line drug for malaria treatment, and trials are ongoing that include this drug in cancer therapy. Despite increasing interest in its therapeutic application, the mode of cell killing provoked by artesunate in human cells is unknown. Here, we show that artesunate is a powerful inducer of oxidative DNA damage, giving rise to formamidopyrimidine DNA glycosylase–sensitive sites and the formation of 8-oxoguanine and 1,N6-ethenoadenine. Oxidative DNA damage was induced in LN-229 human glioblastoma cells dose dependently and was paralleled by cell death executed by ap…

Cancer ResearchProgrammed cell deathDNA RepairRAD51Drug Evaluation PreclinicalArtesunateApoptosisCell Cycle ProteinsAtaxia Telangiectasia Mutated ProteinsBiologyProtein Serine-Threonine KinasesModels Biologicalchemistry.chemical_compoundNeoplasmsTumor Cells CulturedHumansDNA Breaks Double-StrandedTumor Suppressor ProteinsMolecular biologyAntineoplastic Agents PhytogenicArtemisininsUp-RegulationNon-homologous end joiningDNA-Binding ProteinsOxidative StressCell killingOncologychemistryArtesunateApoptosisCancer cellHomologous recombinationDNA DamageMolecular cancer therapeutics
researchProduct

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

2021

[Purpose]: To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab.

Cancer ResearchStromal cellReceptor ErbB-2medicine.medical_treatmentNeuregulin-1Drug Evaluation PreclinicalBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabAntineoplastic Combined Chemotherapy Protocolsmental disordersmedicineTumor Cells CulturedHumansNeuregulin 1skin and connective tissue diseasesneoplasmsNeoadjuvant therapyRetrospective Studiesbiologybusiness.industryFibroblastsTrastuzumabmedicine.diseasebody regionsTreatment OutcomeOncologyCancer cellbiology.proteinCancer researchImmunohistochemistryFemalePertuzumabbusinessmedicine.drug
researchProduct